ArticleInternational journal of nephrology2017
Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study.
Article in International journal of nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- The risk of primary lung cancer in ANCA-associated vasculitis: systematic review and meta-analysis.Proceedings (Baylor University. Medical Center) · 2026Pooled it
- Cancer risk across sex, region, and disease subtype in ANCA-associated vasculitis patients : A meta-analysis.Zeitschrift fur Rheumatologie · 2025Pooled it
- ANCA-associated vasculitis and lung cancer: an immunological perspective.Clinical and experimental medicine · 2024Review
- Kidney transplantation in patients with ANCA-associated vasculitis is associated with a high incidence of post-transplant cancer.Journal of nephrology · 2024Article
- Malignancy is increased in patients with antineutrophil cytoplasmic antibody-associated vasculitis in China.Arthritis research & therapy · 2024Article
- Uncommon Presentation of Granulomatosis with Polyangiitis Mimicking Metastatic Lung Cancer.Clinics and practice · 2021Article
- New lung mass in a patient with granulomatosis with polyangiitis.Rheumatology international · 2021Review
- Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis.Clinical rheumatology · 2020Review
- Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management.Drugs & aging · 2019Review
- Comparison of cancer prevalence between patients with glomerulonephritis and the general population at the time of kidney biopsy.PloS one · 2019Article
- ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives.Journal of immunology research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunosuppressive therapy for antineutrophil cytoplasmic antibody-associated vasculitis has been associated with increased malignancy risk.
objectivesTo quantify the cancer risk associated with contemporary cyclophosphamide-sparing protocols.
methodsPatients from the Norwegian Kidney Biopsy Registry between 1988 and 2012 who had biopsy-verified pauci-immune glomerulonephritis and positive antineutrophil cytoplasmic antibody (ANCA) serology were included. Standardised incidence ratios (SIRs) were calculated to compare the study cohort with the general population.
resultsThe study cohort included 419 patients. During 3010 person-years, cancer developed in 41 patients (9.79%); the expected number of cancer cases was 37.5 (8.95%). The cohort had SIRs as follows: 1.09, all cancer types (95% CI, 0.81 to 1.49); 0.96, all types except nonmelanoma skin cancer (95% CI, 0.69 to 1.34); 3.40, nonmelanoma skin cancer (95% CI, 1.62 to 7.14); 3.52, hematologic cancer (95% CI, 1.32 to 9.37); 2.12, posttransplant cancer (95% CI, 1.01 to 4.44); and 1.53, during the 1-5-year follow-up after diagnosis (95% CI, 1.01 to 2.32).
conclusionsCancer risk did not increase significantly in this cohort with ANCA-associated glomerulonephritis. However, increased risk of nonmelanoma skin cancer, posttransplant cancer, and hematologic cancer indicates an association between immunosuppression and malignancy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.